Literature DB >> 27832050

Progress Toward Regional Measles Elimination - Worldwide, 2000-2015.

Minal K Patel, Marta Gacic-Dobo, Peter M Strebel, Alya Dabbagh, Mick N Mulders, Jean-Marie Okwo-Bele, Laure Dumolard, Paul A Rota, Katrina Kretsinger, James L Goodson.   

Abstract

Adopted in 2000, United Nations Millennium Development Goal 4 set a target to reduce child mortality by two thirds by 2015, with measles vaccination coverage as one of the progress indicators. In 2010, the World Health Assembly (WHA) set three milestones for measles control by 2015: 1) increase routine coverage with the first dose of measles-containing vaccine (MCV1) for children aged 1 year to ≥90% nationally and ≥80% in every district; 2) reduce global annual measles incidence to <5 cases per 1 million population; and 3) reduce global measles mortality by 95% from the 2000 estimate (1,2).* In 2012, WHA endorsed the Global Vaccine Action Plan† with the objective to eliminate measles in four World Health Organization (WHO) regions by 2015. Countries in all six WHO regions have adopted measles elimination goals. Measles elimination is the absence of endemic measles transmission in a region or other defined geographical area for ≥12 months in the presence of a well performing surveillance system. This report updates a previous report (3) and describes progress toward global measles control milestones and regional measles elimination goals during 2000-2015. During this period, annual reported measles incidence decreased 75%, from 146 to 36 cases per 1 million persons, and annual estimated measles deaths decreased 79%, from 651,600 to 134,200. However, none of the 2015 milestones or elimination goals were met. Countries and their partners need to act urgently to secure political commitment, raise the visibility of measles, increase vaccination coverage, strengthen surveillance, and mitigate the threat of decreasing resources for immunization once polio eradication is achieved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27832050     DOI: 10.15585/mmwr.mm6544a6

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  33 in total

1.  Fifty Years of Global Immunization at CDC, 1966-2015.

Authors:  Eric E Mast; Stephen L Cochi; Olen M Kew; K Lisa Cairns; Peter B Bloland; Rebecca Martin
Journal:  Public Health Rep       Date:  2016-12-19       Impact factor: 2.792

2.  Facebook and Twitter vaccine sentiment in response to measles outbreaks.

Authors:  Michael S Deiner; Cherie Fathy; Jessica Kim; Katherine Niemeyer; David Ramirez; Sarah F Ackley; Fengchen Liu; Thomas M Lietman; Travis C Porco
Journal:  Health Informatics J       Date:  2017-11-17       Impact factor: 2.681

3.  Sero-prevalence of rubella among pregnant women in Sub-Saharan Africa: a meta-analysis.

Authors:  Zemenu Yohannes Kassa; Siraj Hussen; Solomon Asnake
Journal:  Hum Vaccin Immunother       Date:  2020-03-20       Impact factor: 3.452

4.  A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques.

Authors:  Jessica C Joyce; Timothy D Carroll; Marcus L Collins; Min-Hsin Chen; Linda Fritts; Joseph C Dutra; Tracy L Rourke; James L Goodson; Michael B McChesney; Mark R Prausnitz; Paul A Rota
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

5.  Measles Antibodies in Mother-Infant Dyads in Tianjin, China.

Authors:  Matthew L Boulton; Xiexiu Wang; Abram L Wagner; Ying Zhang; Bradley F Carlson; Brenda W Gillespie; Yaxing Ding
Journal:  J Infect Dis       Date:  2017-11-27       Impact factor: 5.226

6.  Progress and challenges in measles and rubella elimination in the WHO European Region.

Authors:  Siddhartha Sankar Datta; Patrick Michael O'Connor; Dragan Jankovic; Mark Muscat; Myriam Corrine Ben Mamou; Simarjit Singh; Theodoros Kaloumenos; Susan Reef; Mark Papania; Robb Butler
Journal:  Vaccine       Date:  2017-06-23       Impact factor: 3.641

Review 7.  Current perspectives in assessing humoral immunity after measles vaccination.

Authors:  Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2018-12-26       Impact factor: 5.683

8.  Molecular characterisation of measles virus strains among refugees from Central African Republic in Cameroon in 2014.

Authors:  P K Ndombo; V N Ndze; F D Mbarga; R Anderson; A Acho; J Ebua Chia; A K Njamnshi; P A Rota; D Waku-Kouomou
Journal:  Epidemiol Infect       Date:  2018-01-09       Impact factor: 4.434

9.  Pivoting from polio eradication to measles and rubella elimination: a transition that makes sense both for children and immunization program improvement.

Authors:  Stephen L Cochi
Journal:  Pan Afr Med J       Date:  2017-06-21

10.  Determinants of Incomplete Childhood Vaccination among Children Aged 12-23 Months in Gambela Region, Southwest Ethiopia: A Case Control Study.

Authors:  Asnake Mebrat; Lamessa Dube; Ayantu Kebede; Zemedu Aweke
Journal:  Ethiop J Health Sci       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.